 SOUTH SAN FRANCISCO, Calif., Aug. 17, 2021 GLOBE NEWSWIRE -- CytomX Therapeutics, Inc. Nasdaq: CTMX, a clinical-stage, oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated antibody therapeutics based on its Probody technology platform, today announced that on August 16, 2021, the Company granted seven new employees options to purchase a total of 172,600 shares of the Companys common stock at an exercise price per share equal to 4.81, which was the closing trading price on August 16, 2021, the date of the grant. 